STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the company’s criteria.
“It is a disappointment to discontinue the development program but our product candidates need to meet strict criteria to be approved for continued investments. Our other development programs progresses according to plan and our goal of positive cash flow and operating results 2013 remain unchanged,” said Peter Wolpert, CEO of Moberg Derma.
About this information Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 16:00 pm (CET) on October 27th, 2011.
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox®/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.com
This information was brought to you by Cision http://www.cisionwire.com
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 70- 735 71 35
Magnus Persson, IR
Mobile: +46 73-355 26 01